Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2015

01-10-2015 | Review

Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease

Authors: Ersilia M. DeFilippis, Sonal Kumar

Published in: Digestive Diseases and Sciences | Issue 10/2015

Login to get access

Abstract

Nearly one-third of patients with inflammatory bowel disease (IBD) have abnormal liver tests, which can be indicative of underlying hepatic disease. Primary sclerosing cholangitis has a clear association with ulcerative colitis, but other autoimmune disorders such as autoimmune hepatitis (AIH) have also been associated with IBD. AIH may also occur in the setting of an overlap syndrome or in the setting of medications, particularly tumor necrosis factor alpha inhibitors. Importantly, some studies have shown that IBD patients with AIH fail treatment more frequently than IBD patients without AIH. This review will focus on the clinical characteristics, diagnosis, and management of autoimmune hepatitis in inflammatory bowel disease patients.
Literature
1.
go back to reference Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19:7327–7340.CrossRefPubMedCentralPubMed Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19:7327–7340.CrossRefPubMedCentralPubMed
2.
go back to reference Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598–1619.CrossRefPubMed Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1598–1619.CrossRefPubMed
3.
go back to reference Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008;14:331–337.CrossRefPubMedCentralPubMed Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008;14:331–337.CrossRefPubMedCentralPubMed
4.
go back to reference Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol. 1992;14:325–331.CrossRefPubMed Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol. 1992;14:325–331.CrossRefPubMed
5.
go back to reference Bailey J, Sreepati G, Love J, et al. Autoimmune hepatitis with inflammatory bowel disease is distinct and may be more refractory to traditional treatment. Am J Gastroenterol. 2014;109:S149. Bailey J, Sreepati G, Love J, et al. Autoimmune hepatitis with inflammatory bowel disease is distinct and may be more refractory to traditional treatment. Am J Gastroenterol. 2014;109:S149.
6.
go back to reference Trivedi PJ, Chapman RW. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol. 2012;36:420–436.CrossRefPubMed Trivedi PJ, Chapman RW. PSC, AIH and overlap syndrome in inflammatory bowel disease. Clin Res Hepatol Gastroenterol. 2012;36:420–436.CrossRefPubMed
7.
go back to reference Knight C, Murray KF. Hepatobiliary associations with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009;3:681–691.CrossRefPubMed Knight C, Murray KF. Hepatobiliary associations with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009;3:681–691.CrossRefPubMed
8.
go back to reference Liberal R, Grant CR, Longhi MS, Mieli-Vergani G, Vergani D. Diagnostic criteria of autoimmune hepatitis. Autoimmun Rev. 2014;13:435–440.CrossRefPubMed Liberal R, Grant CR, Longhi MS, Mieli-Vergani G, Vergani D. Diagnostic criteria of autoimmune hepatitis. Autoimmun Rev. 2014;13:435–440.CrossRefPubMed
9.
go back to reference Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.CrossRefPubMed Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–176.CrossRefPubMed
10.
go back to reference Ordonez F, Lacaille F, Canioni D, et al. Pediatric ulcerative colitis associated with autoimmune diseases: a distinct form of inflammatory bowel disease? Inflamm Bowel Dis. 2012;18:1809–1817.CrossRefPubMed Ordonez F, Lacaille F, Canioni D, et al. Pediatric ulcerative colitis associated with autoimmune diseases: a distinct form of inflammatory bowel disease? Inflamm Bowel Dis. 2012;18:1809–1817.CrossRefPubMed
12.
go back to reference Trivedi PP, Jena GB. Ulcerative colitis-induced hepatic damage in mice: studies on inflammation, fibrosis, oxidative DNA damage and GST-P expression. Chem Biol Interact. 2013;201:19–30.CrossRefPubMed Trivedi PP, Jena GB. Ulcerative colitis-induced hepatic damage in mice: studies on inflammation, fibrosis, oxidative DNA damage and GST-P expression. Chem Biol Interact. 2013;201:19–30.CrossRefPubMed
13.
14.
go back to reference Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol. 2013;27:417–423.PubMedCentralPubMed Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol. 2013;27:417–423.PubMedCentralPubMed
15.
go back to reference Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374–385.CrossRefPubMed Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374–385.CrossRefPubMed
16.
go back to reference Rojas CP, Bodicharla R, Campuzano-Zuluaga G, Hernandez L, Rodriguez MM. Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents. Fetal Pediatr Pathol. 2014;33:202–209.CrossRefPubMedCentralPubMed Rojas CP, Bodicharla R, Campuzano-Zuluaga G, Hernandez L, Rodriguez MM. Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents. Fetal Pediatr Pathol. 2014;33:202–209.CrossRefPubMedCentralPubMed
17.
go back to reference Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013;58:1392–1400.CrossRefPubMed Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013;58:1392–1400.CrossRefPubMed
18.
go back to reference Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci. 2013;58:326–343.PubMed Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci. 2013;58:326–343.PubMed
19.
go back to reference Malik TA, Gutierrez AM, McGuire B, Zarzour JG, Mukhtar F, Bloomer J. Autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome complicated by Crohn’s disease. Digestion. 2010;82:24–26.CrossRefPubMed Malik TA, Gutierrez AM, McGuire B, Zarzour JG, Mukhtar F, Bloomer J. Autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome complicated by Crohn’s disease. Digestion. 2010;82:24–26.CrossRefPubMed
20.
go back to reference Durazzo M, Premoli A, Paschetta E, Belci P, Spandre M, Bo S. Overlap syndromes of autoimmune hepatitis: an open question. Dig Dis Sci. 2013;58:344–348.CrossRefPubMed Durazzo M, Premoli A, Paschetta E, Belci P, Spandre M, Bo S. Overlap syndromes of autoimmune hepatitis: an open question. Dig Dis Sci. 2013;58:344–348.CrossRefPubMed
21.
go back to reference Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516–1522.CrossRefPubMed Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100:1516–1522.CrossRefPubMed
22.
go back to reference Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci. 1992;37:1606–1611.CrossRefPubMed Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci. 1992;37:1606–1611.CrossRefPubMed
23.
go back to reference Lawrence SP, Sherman KE, Lawson JM, Goodman ZD. A 39 year old man with chronic hepatitis. Semin Liver Dis. 1994;14:97–105.CrossRefPubMed Lawrence SP, Sherman KE, Lawson JM, Goodman ZD. A 39 year old man with chronic hepatitis. Semin Liver Dis. 1994;14:97–105.CrossRefPubMed
24.
go back to reference Wurbs D, Klein R, Terracciano LM, Berg PA, Bianchi L. A 28-year-old woman with a combined hepatitic/cholestatic syndrome. Hepatology. 1995;22:1598–1605.CrossRefPubMed Wurbs D, Klein R, Terracciano LM, Berg PA, Bianchi L. A 28-year-old woman with a combined hepatitic/cholestatic syndrome. Hepatology. 1995;22:1598–1605.CrossRefPubMed
25.
go back to reference Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology. 1996;23:1369–1376.CrossRefPubMed Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology. 1996;23:1369–1376.CrossRefPubMed
26.
go back to reference Protzer U, Dienes HP, Bianchi L, et al. Post-infantile giant cell hepatitis in patients with primary sclerosing cholangitis and autoimmune hepatitis. Liver. 1996;16:274–282.CrossRefPubMed Protzer U, Dienes HP, Bianchi L, et al. Post-infantile giant cell hepatitis in patients with primary sclerosing cholangitis and autoimmune hepatitis. Liver. 1996;16:274–282.CrossRefPubMed
27.
go back to reference Luketic VA, Gomez DA, Sanyal AJ, Shiffman ML. An atypical presentation for primary sclerosing cholangitis. Dig Dis Sci. 1997;42:2009–2016.CrossRefPubMed Luketic VA, Gomez DA, Sanyal AJ, Shiffman ML. An atypical presentation for primary sclerosing cholangitis. Dig Dis Sci. 1997;42:2009–2016.CrossRefPubMed
28.
go back to reference McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol. 1998;93:777–784.CrossRefPubMed McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol. 1998;93:777–784.CrossRefPubMed
29.
go back to reference Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology. 2002;36:1393–1399.CrossRefPubMed Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology. 2002;36:1393–1399.CrossRefPubMed
30.
go back to reference Van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol.. 2000;33:543–548.CrossRefPubMed Van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol.. 2000;33:543–548.CrossRefPubMed
31.
go back to reference Hatzis GS, Vassiliou VA, Delladetsima JK. Overlap syndrome of primary sclerosing cholangitis and autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2001;13:203–206.CrossRefPubMed Hatzis GS, Vassiliou VA, Delladetsima JK. Overlap syndrome of primary sclerosing cholangitis and autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2001;13:203–206.CrossRefPubMed
32.
go back to reference Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28:360–365.CrossRefPubMed Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28:360–365.CrossRefPubMed
33.
go back to reference Rupp C, Mummelthei A, Sauer P, et al. Non-IBD immunological diseases are a risk factor for reduced survival in PSC. Liver Int. 2013;33:86–93.CrossRefPubMed Rupp C, Mummelthei A, Sauer P, et al. Non-IBD immunological diseases are a risk factor for reduced survival in PSC. Liver Int. 2013;33:86–93.CrossRefPubMed
34.
go back to reference Lüth S, Kanzler S, Frenzel C, et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol. 2009;43:75–80.CrossRefPubMed Lüth S, Kanzler S, Frenzel C, et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. J Clin Gastroenterol. 2009;43:75–80.CrossRefPubMed
35.
go back to reference Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas J Dermatol. 2014;55:75–79.CrossRefPubMed Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas J Dermatol. 2014;55:75–79.CrossRefPubMed
36.
go back to reference Yilmaz B, Roach EC, Koklu S. Infliximab leading to autoimmune hepatitis: an increasingly recognized side effect. Dig Dis Sci. 2014;59:2602–2603.CrossRefPubMed Yilmaz B, Roach EC, Koklu S. Infliximab leading to autoimmune hepatitis: an increasingly recognized side effect. Dig Dis Sci. 2014;59:2602–2603.CrossRefPubMed
37.
go back to reference Doyle A, Forbes G, Kontorinis N. Autoimmune hepatitis during infliximab therapy for Crohn’s disease: a case report. J Crohns Colitis. 2011;5:253–255.CrossRefPubMed Doyle A, Forbes G, Kontorinis N. Autoimmune hepatitis during infliximab therapy for Crohn’s disease: a case report. J Crohns Colitis. 2011;5:253–255.CrossRefPubMed
38.
go back to reference Goldfeld DA, Verna EC, Lefkowitch J, Swaminath A. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn’s disease: the index case. Dig Dis Sci. 2011;56:3386–3388.CrossRefPubMed Goldfeld DA, Verna EC, Lefkowitch J, Swaminath A. Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn’s disease: the index case. Dig Dis Sci. 2011;56:3386–3388.CrossRefPubMed
39.
go back to reference Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn’s disease with no relapse after switching to adalimumab. BioDrugs Clin Immunother Biopharm Gene Therapy. 2010;24:25–27.CrossRef Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn’s disease with no relapse after switching to adalimumab. BioDrugs Clin Immunother Biopharm Gene Therapy. 2010;24:25–27.CrossRef
40.
go back to reference Van Casteren-Messidoro C, Prins G, van Tilburg A, Zelinkova Z, Schouten J, de Man R. Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. J Crohns Colitis. 2012;6:630–631.CrossRefPubMed Van Casteren-Messidoro C, Prins G, van Tilburg A, Zelinkova Z, Schouten J, de Man R. Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. J Crohns Colitis. 2012;6:630–631.CrossRefPubMed
41.
go back to reference Subramaniam K, Chitturi S, Brown M, Pavli P. Infliximab-induced autoimmune hepatitis in Crohn’s disease treated with budesonide and mycophenolate. Inflamm Bowel Dis. 2011;17:E149–E150.CrossRefPubMed Subramaniam K, Chitturi S, Brown M, Pavli P. Infliximab-induced autoimmune hepatitis in Crohn’s disease treated with budesonide and mycophenolate. Inflamm Bowel Dis. 2011;17:E149–E150.CrossRefPubMed
42.
go back to reference Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust. 2007;187:524–526.PubMed Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust. 2007;187:524–526.PubMed
43.
go back to reference Marques M, Magro F, Cardoso H, et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis. 2008;14:723–725.CrossRefPubMed Marques M, Magro F, Cardoso H, et al. Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis. 2008;14:723–725.CrossRefPubMed
44.
go back to reference Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005;64:1519–1520.CrossRefPubMedCentralPubMed Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005;64:1519–1520.CrossRefPubMedCentralPubMed
45.
go back to reference Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol. 2009;34:421–422.CrossRefPubMed Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol. 2009;34:421–422.CrossRefPubMed
46.
go back to reference Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M. BIOGEAS study group: biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56–64.CrossRefPubMed Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M. BIOGEAS study group: biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56–64.CrossRefPubMed
47.
go back to reference Efe C. Drug induced autoimmune hepatitis and TNF-α blocking agents: is there a real relationship? Autoimmun Rev. 2013;12:337–339.CrossRefPubMed Efe C. Drug induced autoimmune hepatitis and TNF-α blocking agents: is there a real relationship? Autoimmun Rev. 2013;12:337–339.CrossRefPubMed
48.
go back to reference Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol. 2008;27:1063–1066.CrossRefPubMed Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol. 2008;27:1063–1066.CrossRefPubMed
49.
go back to reference Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med. 2014;2014:1–5.CrossRef Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med. 2014;2014:1–5.CrossRef
50.
go back to reference Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol. 2010;44:e20–e22.CrossRefPubMed Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol. 2010;44:e20–e22.CrossRefPubMed
51.
go back to reference Eriksson C, Engstrand S, Sundqvist K-G, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403–407.CrossRefPubMedCentralPubMed Eriksson C, Engstrand S, Sundqvist K-G, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403–407.CrossRefPubMedCentralPubMed
52.
go back to reference Tobon GJ, Cañas C, Jaller J-J, Restrepo J-C, Anaya J-M. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26:578–581.CrossRefPubMed Tobon GJ, Cañas C, Jaller J-J, Restrepo J-C, Anaya J-M. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26:578–581.CrossRefPubMed
53.
54.
go back to reference Rajanayagam J, Lewindon PJ. Infliximab as rescue therapy in paediatric autoimmune hepatitis. J Hepatol. 2013;59:908–909.CrossRefPubMed Rajanayagam J, Lewindon PJ. Infliximab as rescue therapy in paediatric autoimmune hepatitis. J Hepatol. 2013;59:908–909.CrossRefPubMed
55.
go back to reference Vallejo Senra N, Fernández Castroagudín J, Molina Pérez E, Domínguez-Muñoz JE. Onset of severe acute autoimmune hepatitis refractory to conventional treatment, rescued with infliximab. Gastroenterol Hepatol. 2014. doi:10.1016/j.gastrohep.2014.02.012. Vallejo Senra N, Fernández Castroagudín J, Molina Pérez E, Domínguez-Muñoz JE. Onset of severe acute autoimmune hepatitis refractory to conventional treatment, rescued with infliximab. Gastroenterol Hepatol. 2014. doi:10.​1016/​j.​gastrohep.​2014.​02.​012.
56.
go back to reference Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58:529–534.CrossRefPubMed Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013;58:529–534.CrossRefPubMed
57.
59.
go back to reference Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987–1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl. 1998;17–37. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987–1998: updated results from the Pitt-UNOS Liver Transplant Registry. Clin Transpl. 1998;17–37.
60.
go back to reference Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transplant. 2002;8:519–526.CrossRef Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transplant. 2002;8:519–526.CrossRef
61.
go back to reference Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res. 2007;37:S462.CrossRefPubMed Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol Res. 2007;37:S462.CrossRefPubMed
62.
go back to reference Prados E, Cuervas-Mons V, de la Mata M, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation. 1998;66:1645–1650.CrossRefPubMed Prados E, Cuervas-Mons V, de la Mata M, et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation. 1998;66:1645–1650.CrossRefPubMed
63.
go back to reference Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation. 1999;68:253–256.CrossRefPubMed Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation. 1999;68:253–256.CrossRefPubMed
64.
go back to reference Aguilera I, Sousa JM, Praena JM, Gómez-Bravo MA, Núñez-Roldan A. Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation. Clin Transplant. 2011;25:207–212.CrossRefPubMed Aguilera I, Sousa JM, Praena JM, Gómez-Bravo MA, Núñez-Roldan A. Choice of calcineurin inhibitor may influence the development of de novo immune hepatitis associated with anti-GSTT1 antibodies after liver transplantation. Clin Transplant. 2011;25:207–212.CrossRefPubMed
65.
go back to reference Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant. 2007;7:955–963.CrossRefPubMed Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant. 2007;7:955–963.CrossRefPubMed
66.
go back to reference Salcedo M, Vaquero J, Bañares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology. 2002;35:349–356.CrossRefPubMed Salcedo M, Vaquero J, Bañares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology. 2002;35:349–356.CrossRefPubMed
67.
go back to reference Kerkar N, Hadzić N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet. 1998;351:409–413.CrossRefPubMed Kerkar N, Hadzić N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet. 1998;351:409–413.CrossRefPubMed
68.
go back to reference Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transplant. 2008;14:1281–1286.CrossRef Campsen J, Zimmerman MA, Trotter JF, et al. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transplant. 2008;14:1281–1286.CrossRef
69.
go back to reference Sandhu A, Alameel T, Dale CH, Levstik M, Chande N. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series. Aliment Pharmacol Ther. 2012;36:159–165.CrossRefPubMed Sandhu A, Alameel T, Dale CH, Levstik M, Chande N. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series. Aliment Pharmacol Ther. 2012;36:159–165.CrossRefPubMed
70.
go back to reference Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6:1422–1429.CrossRefPubMed Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant. 2006;6:1422–1429.CrossRefPubMed
71.
go back to reference Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut.. 1998;43:639–644.CrossRefPubMedCentralPubMed Papatheodoridis GV, Hamilton M, Mistry PK, Davidson B, Rolles K, Burroughs AK. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut.. 1998;43:639–644.CrossRefPubMedCentralPubMed
72.
go back to reference Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol. 1997;92:279–282.PubMed Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol. 1997;92:279–282.PubMed
75.
go back to reference Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn’s disease: a single-center experience. Inflamm Bowel Dis. 2008;14:7–12.CrossRefPubMed Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn’s disease: a single-center experience. Inflamm Bowel Dis. 2008;14:7–12.CrossRefPubMed
76.
go back to reference Fellermann K, Steffen M, Stein J, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:171–176.CrossRefPubMed Fellermann K, Steffen M, Stein J, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:171–176.CrossRefPubMed
Metadata
Title
Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease
Authors
Ersilia M. DeFilippis
Sonal Kumar
Publication date
01-10-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3699-4

Other articles of this Issue 10/2015

Digestive Diseases and Sciences 10/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.